Goldman Sachs raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $37 from $30 and keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
- Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
- NewAmsterdam Pharma Reports Q3 2025 Financial Results
- Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments
- NewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating